Optimal Detection of ALK Rearranged Lung Adenocarcinomas
Ground Glass Nodules
Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells
Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer
Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues
Incidence of Non–Small-Cell Lung Cancer among California Hispanics According to Neighborhood Socioeconomic Status
BRCA1, LMO4, and CtIP mRNA Expression in Erlotinib-Treated Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC
How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?
Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer
Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer
Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer
Explore the Radiotherapeutic Clinical Target Volume Delineation for Thoracic Esophageal Squamous Cell Carcinoma from the Pattern of Lymphatic Metastases
Elderly Patients with Advanced NSCLC in Phase III Clinical Trials
Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer
Epidermal Growth Factor Receptor Inhibition in Lung Cancer
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer
Esophageal Fistula after EUS-FNA in a Patient Treated with Bevacizumab for Non–Small-Cell Lung Cancer
Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR-Mutated NSCLC
Does T790M Disappear? Successful Gefitinib Rechallenge After T790M Disappearance in a Patient With EGFR-Mutant Non–Small-Cell Lung Cancer
Lymph Node Dissection for Lung Cancer